0001209191-21-012207.txt : 20210218
0001209191-21-012207.hdr.sgml : 20210218
20210218210034
ACCESSION NUMBER: 0001209191-21-012207
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aurentz Vincent
CENTRAL INDEX KEY: 0001657494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 21651726
BUSINESS ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 453-7200
MAIL ADDRESS:
STREET 1: C/O ARENA PHARMACEUTICALS, INC.
STREET 2: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Vincent Aurentz
DATE OF NAME CHANGE: 20151103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-16
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001657494
Aurentz Vincent
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
Executive VP and CBO
Common Stock
2021-02-16
4
M
0
2500
14.60
A
29500
D
Common Stock
2021-02-16
4
M
0
24
35.60
A
29524
D
Common Stock
2021-02-16
4
S
0
2524
85.00
D
27000
D
Employee Stock Option (right to buy)
14.60
2021-02-16
4
M
0
2500
0.00
D
2024-02-13
Common Stock
2500
77000
D
Employee Stock Option (right to buy)
35.60
2021-02-16
4
M
0
24
0.00
D
2025-01-19
Common Stock
24
94976
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2021-02-18